Liquidia (NASDAQ:LQDA) Director Sells $12,782,000.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Paul Manning sold 200,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the completion of the sale, the director owned 716,311 shares in the company, valued at $45,779,436.01. This trade represents a 21.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Liquidia Stock Up 1.9%

Shares of Liquidia stock opened at $65.25 on Thursday. Liquidia Corporation has a one year low of $11.85 and a one year high of $66.78. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. The stock’s 50-day moving average is $48.50 and its 200 day moving average is $40.37. The firm has a market cap of $5.80 billion, a price-to-earnings ratio of 466.10 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The company had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. The business’s revenue was up 4187.1% on a year-over-year basis. Equities research analysts anticipate that Liquidia Corporation will post 2.97 EPS for the current year.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after buying an additional 1,700 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Liquidia by 10.7% in the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after buying an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Liquidia by 15.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares during the last quarter. Creative Planning increased its position in Liquidia by 40.7% in the second quarter. Creative Planning now owns 26,840 shares of the company’s stock worth $334,000 after buying an additional 7,765 shares during the last quarter. Finally, Legal & General Group Plc increased its position in Liquidia by 13.4% in the second quarter. Legal & General Group Plc now owns 94,152 shares of the company’s stock worth $1,174,000 after buying an additional 11,111 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on LQDA. Oppenheimer set a $75.00 target price on Liquidia in a research report on Friday, June 5th. Needham & Company LLC upped their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. BTIG Research upped their target price on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Raymond James Financial restated a “strong-buy” rating and set a $68.00 target price on shares of Liquidia in a research report on Thursday, June 4th. Finally, Zacks Research upgraded Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.29.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).